DOCSLIB.ORG

Rare Disease Registries in Europe

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Rare Disease Registries in Europe January 2015 Rare Disease Registries in Europe www.orpha.net Table of contents Methodology 3 List of rare diseases that are covered by the listed registries 4 Summary 13 1- Distribution of registries by country 13 2- Distribution of registries by coverage 14 3- Distribution of registries by affiliation 14 Distribution of registries by country 15 European registries 38 International registries 41 Orphanet Report Series - Rare Disease Registries in Europe - January 2015 2 http://www.orpha.net/orphacom/cahiers/docs/GB/Registries.pdf Methodology Patient registries and databases constitute key instruments to develop clinical research in the field of rare diseases (RD), to improve patient care and healthcare planning. They are the only way to pool data in order to achieve a sufficient sample size for epidemiological and/or clinical research. They are vital to assess the feasibility of clinical trials, to facilitate the planning of appropriate clinical trials and to support the enrolment of patients. Registries of patients treated with orphan drugs are particularly relevant as they allow the gathering of evidence on the effectiveness of the treatment and on its possible side effects, keeping in mind that marketing authorisation is usually granted at a time when evidence is still limited although already somewhat convincing. This report gather the information collected by Orphanet so far, regarding systematic collections of data for a specific disease or a group of diseases. Cancer registries are listed only if they belong to the network RARECARE or focus on a rare form of cancer. The report includes data about EU countries and surrounding countries participating to the Orphanet consortium. The diseases covered by each register are provided with Orpha number which is their identifier in the Orphanet nomenclature. For any questions or comments, please contact us: [email protected] Orphanet Report Series - Rare Disease Registries in Europe - January 2015 http://www.orpha.net/orphacom/cahiers/docs/GB/Registries.pdf 3 List of rare diseases that are covered by the listed registries ORPHA ORPHA ORPHA Disease name Disease name Disease name Number Number Number 3718 3C syndrome 514 Acute monoblastic leukemia 417 Angelman syndrome 1031 46,XX disorder of sex development 519 Acute myeloid leukemia 1572 Ankyloblepharon - ectodermal defects - cleft lip/palate 98078 46,XX disorder of sex development 517 Acute myelomonocytic leukemia induced by androgens excess 1587 Anonychia - microcephaly 35889 Acute opioid poisoning 1002 46,XY disorder of sex development due to 2858 Anophthalmia - megalocornea - 520 Acute promyelocytic leukemia 17-beta-hydroxysteroid dehydrogenase 3 cardiopathy - skeletal anomalies deficiency 309120 Acyl-CoA dehydrogenase deficiency 1593 Anophthalmia plus syndrome 94 46,XY disorder of sex development due to 55881 Adamantinoma 96346 Anorectal malformation 5-alpha-reductase 2 deficiency 85138 Addison disease 3482 Anti-glomerular basement membrane 325351 46,XY disorder of sex development of 3710 Adducted thumbs - arthrogryposis, disease endocrine origin Christian type 80 Antiphospholipid syndrome 34 6-pyruvoyl-tetrahydropterin synthase 8641 Adenosine monophosphate deaminase 3032 Aortic arch interruption deficiency deficiency 59 Apert syndrome 3009 Aase-Smith syndrome 100091 Adrenal/paraganglial tumor 320 Apparent mineralocorticoid excess 258 Ablepharon macrostomia syndrome 1501 Adrenocortical carcinoma 2878 Arachnodactyly - abnormal ossification - 1490 Abruzzo-Erickson syndrome 2792 Adult familial nephronophthisis - spastic intellectual disability 7030 Absent tibia - polydactyly quadriparesia 3457 Arachnodactyly - intellectual disability - 235 Acatalasemia 1530 ADULT syndrome dysmorphism 48818 Aceruloplasminemia 829 Adult-onset Still disease 1609 AREDYLD syndrome 462 Achondroplasia 83617 Agammaglobulinemia - microcephaly - 508 Argininemia craniosynostosis - severe dermatitis 49382 Achromatopsia 8642 Argininosuccinic aciduria 52055 Agenesis of the corpus callosum 2207 Ackerman syndrome - intellectual disability - coloboma - 8607 Arnold-Chiari malformation type II 101963 Acquired chronic primary adrenal micrognathia 2853 Arrhinia insufficiency 86873 Aggressive NK-cell leukemia 247 Arrhythmogenic right ventricular dysplasia 861 Acrocraniofacial dysostosis 1536 Agnathia - holoprosencephaly - situs 3387 Arterial tortuosity syndrome 3082 Acrodermatitis enteropathica inversus 5522 Arthrogryposis - renal dysfunction - 1789 Acrofacial dysostosis, Catania type 484 Albers-Schönberg osteopetrosis cholestasis 64542 Acrofacial dysostosis, Kennedy-Teebi type 565 Allergic bronchopulmonary aspergillosis 982 Arthrogryposis multiplex congenita 1787 Acrofacial dysostosis, Palagonia type 3644 Alopecia - epilepsy - pyorrhea - 1666 Ascher syndrome intellectual disability 3140 Acrofacial dysostosis, Rodríguez type 94 Astrocytoma 1542 Alopecia-contractures-dwarfism- 3187 Acrofacial dysostosis, Weyers type intellectual disability syndrome 167 Ataxia-telangiectasia 1788 Acro-fronto-facio-nasal dysostosis 989 Alpha-1-antitrypsin deficiency 8694 Atresia of small intestine 79356 Acrokeratoderma 4040 Alpha-mannosidosis 8608 Atypical hemolytic-uremic syndrome 1518 Acromegaloid facial appearance syndrome 254 Alpha-thalassemia 77300 Auricular abnormalities - cleft lip 463 Acromegaly with or without cleft palate - ocular 7020 Alport syndrome abnormalities 1522 Acromicric dysplasia 1551 Alström syndrome 71270 Auriculoocular anomalies - cleft lip 1511 Acroosteolysis dominant type 8746 Alternating hemiplegia of childhood 98375 Autoimmune hemolytic anemia 1524 Acrorenal syndrome 8658 Alveolar echinococcosis 2554 Autoimmune polyendocrinopathy type 2 1513 Acro-renal-mandibular syndrome 1450 Amelo-cerebro-hypohidrotic syndrome 71203 Autoimmune thrombocytopenia 99892 ACTH-dependent Cushing syndrome 88661 Amelogenesis imperfecta 93665 Autoinflammatory syndrome 318 Acute erythroid leukemia 1558 Amelogenesis imperfecta - 8734 Autosomal dominant cerebellar ataxia 293173 Acute generalized exanthematous nephrocalcinosis pustulosis 94145 Autosomal dominant cerebellar ataxia 1748 Aminopterin/methotrexate type 1 79276 Acute intermittent porphyria embryofetopathy 94148 Autosomal dominant cerebellar ataxia 79126 Acute interstitial pneumonia 312 Amyotrophic lateral sclerosis type 3 513 Acute lymphoblastic leukemia 1245 Androgen insensitivity syndrome 73229 Autosomal dominant familial hematuria - 518 Acute megakaryoblastic leukemia 157954 ANE syndrome retinal arteriolar tortuosity - contractures 4 Orphanet Report Series - Rare Disease Registries in Europe - January 2015 http://www.orpha.net/orphacom/cahiers/docs/GB/Registries.pdf ORPHA ORPHA ORPHA Disease name Disease name Disease name Number Number Number 4048 Autosomal dominant hyper-IgE syndrome 1691 Brachymorphism - onychodysplasia - 726 Classical homocystinuria dysphalangism 34149 Autosomal dominant medullary 8530 Cleft lip with or without cleft palate cystic kidney disease with or without 3195 Branchio-oculo-facial syndrome 1892 Cleft lip/palate - intestinal malrotation - hyperuricemia 1697 Branchio-skeleto-genital syndrome cardiopathy 3155 Autosomal dominant osteosclerosis, Worth 97287 Bronchial endocrine tumor 1351 Cleft palate type 1303 Bronchiolitis obliterans with obstructive 2817 Cleft palate - short stature - vertebral 5013 Autosomal dominant polycystic kidney pulmonary disease anomalies disease 70589 Bronchopulmonary dysplasia 1198 Cleft palate - stapes fixation - oligodontia 3252 Autosomal dominant severe congenital neutropenia 8029 Budd-Chiari syndrome 1200 Cleft palate-lateral synechia syndrome 3619 Autosomal dominant spondylocostal 703 Bullous pemphigoid 8565 Cleidocranial dysplasia dysostosis 543 Burkitt lymphoma 930 Cockayne syndrome 1172 Autosomal recessive cerebellar ataxia 1359 C syndrome 1741 CODAS syndrome 34515 Autosomal recessive limb-girdle muscular 329931 C3 glomerulonephritis 1043 Coffin-Lowry syndrome dystrophy type 2I 1313 CADASIL 2566 COFS syndrome 264 Autosomal recessive polycystic kidney disease 280062 Calciphylaxis 92 Cohen syndrome 700 Autosomal recessive primary microcephaly 1706 Cantrell pentalogy 31824 Colchicine poisoning 3070 Autosomal recessive spondylocostal 137667 Capillary malformation - arteriovenous 157820 Cold-induced sweating syndrome malformation dysostosis 1081 Colonic atresia 42 Carbamoyl-phosphate synthase deficiency 782 Axenfeld-Rieger syndrome 35909 Combined deficiency of factor V and 1653 Bamforth-Lazarus syndrome 1220 Cardiocranial syndrome, Pfeiffer type factor VIII 1656 Barber-Say syndrome 1365 Carey-Fineman-Ziter syndrome 3049 Common variable immunodeficiency 2901 Bardet-Biedl syndrome 97286 Carney-Stratakis syndrome 965 Complete atrioventricular canal 415 Barth syndrome 65759 Carpenter syndrome 1822 Cone rod dystrophy 818 Bartsocas-Papas syndrome 160 Castleman disease 1526 Congenital absence/hypoplasia of fingers excluding thumb, unilateral 67038 B-cell chronic lymphocytic leukemia 1094 Cataract - intellectual disability - hypogonadism 206 Congenital adrenal hyperplasia 86852 B-cell prolymphocytic leukemia 540 Catecholamine-producing tumor 2807 Congenital bronchobiliary fistula 98895 Becker muscular dystrophy 1095 Catel-Manzke syndrome 532 Congenital diaphragmatic hernia 8722 Beckwith-Wiedemann syndrome 478 Cat-eye syndrome 137 Congenital disorder of glycosylation 1658 Beemer-Ertbruggen syndrome 1265 Caudal regression sequence 98873 Congenital dyserythropoietic anemia type 8663 Behçet disease II 86870 CD4+/CD56+ hematodermic neoplasm 38 Bernard-Soulier syndrome
Load more

Recommended publications
  • CADASIL Testing
    Lab Management Guidelines V1.0.2020 CADASIL Testing MOL.TS.144.A v1.0.2020 Introduction CADASIL testing is addressed by this guideline. Procedures addressed The inclusion of any procedure code in this table does not imply that the code is under management or requires prior authorization. Refer to the specific Health Plan's procedure code list for management requirements. Procedures addressed by this Procedure codes guideline NOTCH3 Known Familial Mutation 81403 Analysis NOTCH3 Targeted Sequencing 81406 NOTCH3 Deletion/Duplication Analysis 81479 What is CADASIL Definition CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is an adult-onset form of cerebrovascular disease. There are no generally accepted clinical diagnostic criteria for CADASIL and symptoms vary among affected individuals. Signs and symptoms Typical signs and symptoms include1,2,3 Transient ischemic attacks and ischemic stroke, occurs at a mean age of 47 years (age range 20-70 years), in most cases without conventional vascular risk factors cognitive disturbance, primarily affecting executive function, may start as early as age 35 years psychiatric or behavioral abnormalities migraine with aura, occurs with a mean age of onset of 30 years (age range 6-48 years), and Less common symptoms include: © 2020 eviCore healthcare. All Rights Reserved. 1 of 7 400 Buckwalter Place Boulevard, Bluffton, SC 29910 (800) 918-8924 www.eviCore.com Lab Management Guidelines V1.0.2020 recurrent seizures with onset in middle age, usually secondary to stroke acute encephalopathy, with a mean age of onset of 42 years Life expectancy for men with CADASIL is reduced by approximately five years and for women by 1 to 2 years.4 Diagnosis Brain Magnetic Resonance Imaging (MRI) findings include T2-signal-abnormalities in the white matter of the temporal pole and T2-signal-abnormalities in the external capsule and corpus callosum.1,2 CADASIL is suspected in an individual with the clinical signs and MRI findings.
    [Show full text]
  • Glossary for Narrative Writing
    Periodontal Assessment and Treatment Planning Gingival description Color: o pink o erythematous o cyanotic o racial pigmentation o metallic pigmentation o uniformity Contour: o recession o clefts o enlarged papillae o cratered papillae o blunted papillae o highly rolled o bulbous o knife-edged o scalloped o stippled Consistency: o firm o edematous o hyperplastic o fibrotic Band of gingiva: o amount o quality o location o treatability Bleeding tendency: o sulcus base, lining o gingival margins Suppuration Sinus tract formation Pocket depths Pseudopockets Frena Pain Other pathology Dental Description Defective restorations: o overhangs o open contacts o poor contours Fractured cusps 1 ww.links2success.biz [email protected] 914-303-6464 Caries Deposits: o Type . plaque . calculus . stain . matera alba o Location . supragingival . subgingival o Severity . mild . moderate . severe Wear facets Percussion sensitivity Tooth vitality Attrition, erosion, abrasion Occlusal plane level Occlusion findings Furcations Mobility Fremitus Radiographic findings Film dates Crown:root ratio Amount of bone loss o horizontal; vertical o localized; generalized Root length and shape Overhangs Bulbous crowns Fenestrations Dehiscences Tooth resorption Retained root tips Impacted teeth Root proximities Tilted teeth Radiolucencies/opacities Etiologic factors Local: o plaque o calculus o overhangs 2 ww.links2success.biz [email protected] 914-303-6464 o orthodontic apparatus o open margins o open contacts o improper
    [Show full text]
  • Oral Health in Prevalent Types of Ehlers–Danlos Syndromes
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Ghent University Academic Bibliography J Oral Pathol Med (2005) 34: 298–307 ª Blackwell Munksgaard 2005 Æ All rights reserved www.blackwellmunksgaard.com/jopm Oral health in prevalent types of Ehlers–Danlos syndromes Peter J. De Coster1, Luc C. Martens1, Anne De Paepe2 1Department of Paediatric Dentistry, Centre for Special Care, Paecamed Research, Ghent University, Ghent; 2Centre for Medical Genetics, Ghent University Hospital, Ghent, Belgium BACKGROUND: The Ehlers–Danlos syndromes (EDS) Introduction comprise a heterogenous group of heritable disorders of connective tissue, characterized by joint hypermobility, The Ehlers–Danlos syndromes (EDS) comprise a het- skin hyperextensibility and tissue fragility. Most EDS erogenous group of heritable disorders of connective types are caused by mutations in genes encoding different tissue, largely characterized by joint hypermobility, skin types of collagen or enzymes, essential for normal pro- hyperextensibility and tissue fragility (1) (Fig. 1). The cessing of collagen. clinical features, modes of inheritance and molecular METHODS: Oral health was assessed in 31 subjects with bases differ according to the type. EDS are caused by a EDS (16 with hypermobility EDS, nine with classical EDS genetic defect causing an error in the synthesis or and six with vascular EDS), including signs and symptoms processing of collagen types I, III or V. The distribution of temporomandibular disorders (TMD), alterations of and function of these collagen types are displayed in dental hard tissues, oral mucosa and periodontium, and Table 1. At present, two classifications of EDS are was compared with matched controls.
    [Show full text]
  • The National Economic Burden of Rare Disease Study February 2021
    Acknowledgements This study was sponsored by the EveryLife Foundation for Rare Diseases and made possible through the collaborative efforts of the national rare disease community and key stakeholders. The EveryLife Foundation thanks all those who shared their expertise and insights to provide invaluable input to the study including: the Lewin Group, the EveryLife Community Congress membership, the Technical Advisory Group for this study, leadership from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), the Undiagnosed Diseases Network (UDN), the Little Hercules Foundation, the Rare Disease Legislative Advocates (RDLA) Advisory Committee, SmithSolve, and our study funders. Most especially, we thank the members of our rare disease patient and caregiver community who participated in this effort and have helped to transform their lived experience into quantifiable data. LEWIN GROUP PROJECT STAFF Grace Yang, MPA, MA, Vice President Inna Cintina, PhD, Senior Consultant Matt Zhou, BS, Research Consultant Daniel Emont, MPH, Research Consultant Janice Lin, BS, Consultant Samuel Kallman, BA, BS, Research Consultant EVERYLIFE FOUNDATION PROJECT STAFF Annie Kennedy, BS, Chief of Policy and Advocacy Julia Jenkins, BA, Executive Director Jamie Sullivan, MPH, Director of Policy TECHNICAL ADVISORY GROUP Annie Kennedy, BS, Chief of Policy & Advocacy, EveryLife Foundation for Rare Diseases Anne Pariser, MD, Director, Office of Rare Diseases Research, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health Elisabeth M. Oehrlein, PhD, MS, Senior Director, Research and Programs, National Health Council Christina Hartman, Senior Director of Advocacy, The Assistance Fund Kathleen Stratton, National Academies of Science, Engineering and Medicine (NASEM) Steve Silvestri, Director, Government Affairs, Neurocrine Biosciences Inc.
    [Show full text]
  • COVID-19 Vaccine Janssen: Contraindication in Individuals with Previous Capillary Leak Syndrome and Update on Thrombosis with Thrombocytopenia Syndrome
    Janssen Sciences Ireland UC Address: Airton Road, Tallaght, D24 WR89 Tel: +353 1 466 5200 Fax: +353 1 431 1058 www.janssen.ie 19the July 2021 COVID-19 Vaccine Janssen: Contraindication in individuals with previous capillary leak syndrome and update on thrombosis with thrombocytopenia syndrome Dear Healthcare Professional, Janssen-Cilag International NV in agreement with the European Medicines Agency and the Health Products Regulatory Authority (HPRA) would like to inform you of the following: Summary Capillary leak syndrome (CLS): • Very rare cases of capillary leak syndrome (CLS) have been reported in the first days after vaccination with COVID-19 Vaccine Janssen, in some cases with a fatal outcome. A history of CLS has been reported in at least one case. • COVID-19 Vaccine Janssen is now contraindicated in individuals who have previously experienced episodes of CLS. • CLS is characterised by acute episodes of oedema mainly affecting the limbs, hypotension, haemoconcentration and hypoalbuminaemia. Patients with an acute episode of CLS following vaccination require prompt recognition and treatment. Intensive supportive therapy is usually warranted. Thrombosis with thrombocytopenia syndrome (TTS): • Individuals diagnosed with thrombocytopenia within 3 weeks after vaccination with COVID-19 Vaccine Janssen should be actively investigated for signs of thrombosis. Similarly, individuals who present with thrombosis within 3 weeks of vaccination should be evaluated for thrombocytopenia. • TTS requires specialised clinical management. Healthcare professionals should consult applicable guidance and/ or consult specialists (e.g., haematologists, specialists in coagulation) to diagnose and treat this condition. Background on the safety concern COVID-19 Vaccine Janssen suspension for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older.
    [Show full text]
  • Non-Syndromic Occurrence of True Generalized Microdontia with Mandibular Mesiodens - a Rare Case Seema D Bargale* and Shital DP Kiran
    Bargale and Kiran Head & Face Medicine 2011, 7:19 http://www.head-face-med.com/content/7/1/19 HEAD & FACE MEDICINE CASEREPORT Open Access Non-syndromic occurrence of true generalized microdontia with mandibular mesiodens - a rare case Seema D Bargale* and Shital DP Kiran Abstract Abnormalities in size of teeth and number of teeth are occasionally recorded in clinical cases. True generalized microdontia is rare case in which all the teeth are smaller than normal. Mesiodens is commonly located in maxilary central incisor region and uncommon in the mandible. In the present case a 12 year-old boy was healthy; normal in appearance and the medical history was noncontributory. The patient was examined and found to have permanent teeth that were smaller than those of the average adult teeth. The true generalized microdontia was accompanied by mandibular mesiodens. This is a unique case report of non-syndromic association of mandibular hyperdontia with true generalized microdontia. Keywords: Generalised microdontia, Hyperdontia, Permanent dentition, Mandibular supernumerary tooth Introduction [Ullrich-Turner syndrome], Chromosome 13[trisomy 13], Microdontia is a rare phenomenon. The term microdontia Rothmund-Thomson syndrome, Hallermann-Streiff, Oro- (microdentism, microdontism) is defined as the condition faciodigital syndrome (type 3), Oculo-mandibulo-facial of having abnormally small teeth [1]. According to Boyle, syndrome, Tricho-Rhino-Phalangeal, type1 Branchio- “in general microdontia, the teeth are small, the crowns oculo-facial syndrome. short, and normal contact areas between the teeth are fre- Supernumerary teeth are defined as any supplementary quently missing” [2] Shafer, Hine, and Levy [3] divided tooth or tooth substance in addition to usual configuration microdontia into three types: (1) Microdontia involving of twenty deciduous and thirty two permanent teeth [7].
    [Show full text]
  • Spectrum of PEX1 and PEX6 Variants in Heimler Syndrome
    European Journal of Human Genetics (2016) 24, 1565–1571 Official Journal of The European Society of Human Genetics www.nature.com/ejhg ARTICLE Spectrum of PEX1 and PEX6 variants in Heimler syndrome Claire EL Smith1, James A Poulter1, Alex V Levin2,3,4, Jenina E Capasso4, Susan Price5, Tamar Ben-Yosef6, Reuven Sharony7, William G Newman8,9, Roger C Shore10, Steven J Brookes10, Alan J Mighell1,11,12 and Chris F Inglehearn*,1,12 Heimler syndrome (HS) consists of recessively inherited sensorineural hearing loss, amelogenesis imperfecta (AI) and nail abnormalities, with or without visual defects. Recently HS was shown to result from hypomorphic mutations in PEX1 or PEX6,both previously implicated in Zellweger Syndrome Spectrum Disorders (ZSSD). ZSSD are a group of conditions consisting of craniofacial and neurological abnormalities, sensory defects and multi-organ dysfunction. The finding of HS-causing mutations in PEX1 and PEX6 shows that HS represents the mild end of the ZSSD spectrum, though these conditions were previously thought to be distinct nosological entities. Here, we present six further HS families, five with PEX6 variants and one with PEX1 variants, and show the patterns of Pex1, Pex14 and Pex6 immunoreactivity in the mouse retina. While Ratbi et al. found more HS-causing mutations in PEX1 than in PEX6, as is the case for ZSSD, in this cohort PEX6 variants predominate, suggesting both genes play a significant role in HS. The PEX6 variant c.1802G4A, p.(R601Q), reported previously in compound heterozygous state in one HS and three ZSSD cases, was found in compound heterozygous state in three HS families.
    [Show full text]
  • Advances in Understanding the Genetics of Syndromes Involving Congenital Upper Limb Anomalies
    Review Article Page 1 of 10 Advances in understanding the genetics of syndromes involving congenital upper limb anomalies Liying Sun1#, Yingzhao Huang2,3,4#, Sen Zhao2,3,4, Wenyao Zhong1, Mao Lin2,3,4, Yang Guo1, Yuehan Yin1, Nan Wu2,3,4, Zhihong Wu2,3,5, Wen Tian1 1Hand Surgery Department, Beijing Jishuitan Hospital, Beijing 100035, China; 2Beijing Key Laboratory for Genetic Research of Skeletal Deformity, Beijing 100730, China; 3Medical Research Center of Orthopedics, Chinese Academy of Medical Sciences, Beijing 100730, China; 4Department of Orthopedic Surgery, 5Department of Central Laboratory, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China Contributions: (I) Conception and design: W Tian, N Wu, Z Wu, S Zhong; (II) Administrative support: All authors; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: Y Huang; (V) Data analysis and interpretation: L Sun; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Wen Tian. Hand Surgery Department, Beijing Jishuitan Hospital, Beijing 100035, China. Email: [email protected]. Abstract: Congenital upper limb anomalies (CULA) are a common birth defect and a significant portion of complicated syndromic anomalies have upper limb involvement. Mostly the mortality of babies with CULA can be attributed to associated anomalies. The cause of the majority of syndromic CULA was unknown until recently. Advances in genetic and genomic technologies have unraveled the genetic basis of many syndromes- associated CULA, while at the same time highlighting the extreme heterogeneity in CULA genetics. Discoveries regarding biological pathways and syndromic CULA provide insights into the limb development and bring a better understanding of the pathogenesis of CULA.
    [Show full text]
  • Capillary Leak Syndrome
    The Medicine Forum Volume 17 Article 8 2016 Case Report: Uncontrolled Anasarca: Capillary Leak Syndrome Ankita Mehta, MD Thomas Jefferson University Hospital, [email protected] Mansi Shah, MD Jefferson Hospital Ambulatory Practice, Thomas Jefferson University Hospital, [email protected] Follow this and additional works at: https://jdc.jefferson.edu/tmf Part of the Internal Medicine Commons, and the Oncology Commons Let us know how access to this document benefits ouy Recommended Citation Mehta, MD, Ankita and Shah, MD, Mansi (2016) "Case Report: Uncontrolled Anasarca: Capillary Leak Syndrome," The Medicine Forum: Vol. 17 , Article 8. DOI: https://doi.org/10.29046/TMF.017.1.009 Available at: https://jdc.jefferson.edu/tmf/vol17/iss1/8 This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in The Medicine Forum by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [email protected]. Mehta, MD and Shah, MD: Case Report: Uncontrolled Anasarca: Capillary Leak Syndrome ONCOLOGY Case Report: Uncontrolled Anasarca: Capillary Leak Syndrome Ankita Mehta, MD, and Mansi Shah, MD INTRODUCTION progression of her pancreatic cancer. She was ultimately discharged home with hospice care.
    [Show full text]
  • Saethre-Chotzen Syndrome
    Saethre-Chotzen syndrome Authors: Professor L. Clauser1 and Doctor M. Galié Creation Date: June 2002 Update: July 2004 Scientific Editor: Professor Raoul CM. Hennekam 1Department of craniomaxillofacial surgery, St. Anna Hospital and University, Corso Giovecca, 203, 44100 Ferrara, Italy. [email protected] Abstract Keywords Disease name and synonyms Excluded diseases Definition Prevalence Management including treatment Etiology Diagnostic methods Genetic counseling Antenatal diagnosis Unresolved questions References Abstract Saethre-Chotzen Syndrome (SCS) is an inherited craniosynostotic condition, with both premature fusion of cranial sutures (craniostenosis) and limb abnormalities. The most common clinical features, present in more than a third of patients, consist of coronal synostosis, brachycephaly, low frontal hairline, facial asymmetry, hypertelorism, broad halluces, and clinodactyly. The estimated birth incidence is 1/25,000 to 1/50,000 but because the phenotype can be very mild, the entity is likely to be underdiagnosed. SCS is inherited as an autosomal dominant trait with a high penetrance and variable expression. The TWIST gene located at chromosome 7p21-p22, is responsible for SCS and encodes a transcription factor regulating head mesenchyme cell development during cranial tube formation. Some patients with an overlapping SCS phenotype have mutations in the FGFR3 (fibroblast growth factor receptor 3) gene; especially the Pro250Arg mutation in FGFR3 (Muenke syndrome) can resemble SCS to a great extent. Significant intrafamilial
    [Show full text]
  • Molecular Delineation of Small Supernumerary Marker
    Zhou et al. Molecular Cytogenetics (2020) 13:19 https://doi.org/10.1186/s13039-020-00486-2 RESEARCH Open Access Molecular delineation of small supernumerary marker chromosomes using a single nucleotide polymorphism array Lili Zhou1, Zhaoke Zheng1, Lianpeng Wu2, Chenyang Xu1, Hao Wu1, Xueqin Xu1 and Shaohua Tang1,2* Abstract Background: Defining the phenotype-genotype correlation of small supernumerary marker chromosomes (sSMCs) remains a challenge in prenatal diagnosis. We karyotyped 20,481 amniotic fluid samples from pregnant women and explored the molecular characteristics of sSMCs using a single nucleotide polymorphism (SNP) array. Results: Out of the 20,481 samples, 15 abnormal karyotypes with sSMC were detected (frequency: 0.073%) and the chromosomal origin was successfully identified by SNP array in 14 of them. The origin of sSMCs were mainly acrocentric-derived chromosomes and the Y chromosome. Two cases of sSMC combined with uniparental disomy (UPD) were detected, UPD(1) and UPD(22). More than half of the cases of sSMC involved mosaicism (8/15) and pathogenicity (9/15) in prenatal diagnosis. A higher prevalence of mosaicism for non-acrocentric chromosomes than acrocentric chromosomes was also revealed. One sSMC derived from chromosome 3 with a neocentromere revealed a 24.99-Mb pathogenic gain of the 3q26.31q29 region on the SNP array, which presented as an abnormal ultrasound indicating nasal bone hypoplasia. Conclusion: The clinical phenotypes of sSMCs are variable and so further genetic testing and parental karyotype analysis are needed to confirm the characteristics of sSMCs. The SNP array used here allows a detailed characterisation of the sSMC and establishes a stronger genotype-phenotype correlation, thus allowing detailed genetic counselling for prenatal diagnosis.
    [Show full text]
  • MEDICAL GENETICS RESIDENCY PROGRAM Department of Pediatrics
    MEDICAL GENETICS RESIDENCY PROGRAM Department of Pediatrics University of Michigan Health Systems (734) 763-6767 1500 E. Medical Center Drive (734) 763-6561 (fax) D5240 MPB Ann Arbor, MI 48109-5718 Biochemical Genetics Goals and Objectives Director: Drs. Ayesha Ahmad and Shane C. Quinonez The goals and objectives of the Biochemical Genetics Clinic rotation in the Medical Genetics Residency Program are to provide the resident with exposure to all aspects of care of metabolic disease and counseling in accordance with the Residency Review Committee for Medical Genetics expectations and to fulfill criteria for board eligibility by the American Board of Medical Genetics. Patient Care The resident will become familiar with the evaluation, diagnosis and management of urea cycle disorders, organic acidemias, disorders of carbohydrate and lipid metabolism and numerous other inborn errors of metabolism (IEMs). Residents will gain exposure in performing and expertise in interpreting biochemical analyses relevant to the diagnosis and management of human genetic diseases. By the end of the rotation the resident should be able to identify signs and symptoms of IEMs, formulate a differential diagnosis, order appropriate tests and recognize normal variants and complex patterns of metabolites. Residents will be able to manage acute metabolic crises and provide chronic management of patients with an IEM. Residents should be able to interpret NBS results, collaborate with the primary provider to act upon results in a timely manner, develop a differential diagnosis and order appropriate confirmatory testing and communicate results to families. Medical Knowledge Through coursework and didactic sessions with attending physicians, residents will become familiar with fundamental concepts, molecular biology and biochemistry relevant to IEMs.
    [Show full text]